Screening for potential infections in fecal microbiota transplantation guidelines and an experience of microbiota bank operation in Korea: a narrative review
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Fecal microbiota transplantation (FMT) involves the transfer of fecal microbiota from healthy donors to patients to rectify dysbiosis and restore the functionality of the gut microbiota to a healthy state. Donor selection is important to minimize the risk of FMT. Donor selectionfor FMT is primarily focused on screening for potential infections. A complete consensus on screening tests and checkpoints is lacking and controversial; nevertheless, most guidelines agree to rule out certain infections, such as syphilis; hepatitis A, B, and C; and HIV. In most guidelines, stool testing includes testing for Clostridioides difficile and other enteric pathogens. The Korean FMT guidelines for C. difficile infections were published in 2022. The guidelines recommend serological and stool testing for donor candidates, with recommendations for stool testing providing targets for screening using specific test methods. Donor screening by Microbiotix Inc., a fecal microbiota bank in Korea, between 2017 and 2023 showed that only5% of potential FMT donors were eligible for repeat donation. The future of FMT remains uncertain, with possibilities ranging from continuation to restrictions, and the development of synthetic microbiota preparations. Legislative support is crucial for advancing this field and providing hope and a potential cure for previously incurable patients.
Abstract
Fecal microbiota transplantation (FMT) involves the transfer of fecal microbiota from healthy donors to patients to rectify dysbiosis and restore the functionality of the gut microbiota to a healthy state. Donor selection is important to minimize the risk of FMT. Donor selectionfor FMT is primarily focused on screening for potential infections. A complete consensus on screening tests and checkpoints is lacking and controversial; nevertheless, most guidelines agree to rule out certain infections, such as syphilis; hepatitis A, B, and C; and HIV. In most guidelines, stool testing includes testing for Clostridioides difficile and other enteric pathogens. The Korean FMT guidelines for C. difficile infections were published in 2022. The guidelines recommend serological and stool testing for donor candidates, with recommendations for stool testing providing targets for screening using specific test methods. Donor screening by Microbiotix Inc., a fecal microbiota bank in Korea, between 2017 and 2023 showed that only5% of potential FMT donors were eligible for repeat donation. The future of FMT remains uncertain, with possibilities ranging from continuation to restrictions, and the development of synthetic microbiota preparations. Legislative support is crucial for advancing this field and providing hope and a potential cure for previously incurable patients.
참고문헌 (17)
- Qu Z, "Fecal microbiota transplantation for diseases : therapeutic potential, methodology, risk management in clinical practice", Life Sci, 304, pp.120719~ (2022)
- Waller KMJ, "An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases", J Gastroenterol Hepatol, 37, pp.246~255 (2022)
- Biazzo M, "Fecal microbiota transplantation as new therapeutic avenue for human diseases", J Clin Med, 11, pp.4119~ (2022)
- Moon CM, "Fecal microbiota transplantation beyond Clostridioides difficile infection", Clin Endosc, 54, pp.149~151 (2021)
- Kang GU, "Exploration of potential gut microbiota-derived biomarkers to predict the success of fecal microbiota transplantation in ulcerative colitis : a prospective cohort in Korea", Gut Liver, 16, pp.775~785 (2022)
- Park JH, "Clinical usefulness of fecal microbiota transplantation", J Neurogastroenterol Motil, 23, pp.149~150 (2017)
- Gweon TG, "Recognition and attitudes of Korean physicians toward fecal microbiota transplantation : a survey study", Korean J Intern Med, 38, pp.48~55 (2023)
- Cammarota G, "European consensus conference on faecal microbiota transplantation in clinical practice", Gut, 66, pp.569~580 (2017)
- Cammarota G, "International consensus conference on stool banking for faecal microbiota transplantation in clinical practice", Gut, 68, pp.2111~2121 (2019)
- Gweon TG, "Clinical practice guidelines for fecal microbiota transplantation in Korea", J Neurogastroenterol Motil, 28, pp.28~42 (2022)
- Barnes D, "Donor considerations in fecal microbiota transplantation", Curr Gastroenterol Rep, 19, pp.10~ (2017)
- "Fecal microbiota fortransplantation: safety alert - risk of serious adverse events likely due to transmission of pathogenic organisms"[URL]
- Xiao F, "Evidence for gastrointestinal infection of SARS-CoV-2", Gastroenterology, 158, pp.1831~1833 (2020)
- Wang W, "Detection of SARS-CoV-2 in different types of clinical specimens", JAMA, 323, pp.1843~1844 (2020)
- Woodworth MH, "Laboratory testing of donors and stool samples for fecal microbiota transplantation for recurrent Clostridium difficile infection", J Clin Microbiol, 55, pp.1002~1010 (2017)
- Seong H, "Fecal microbiota transplantation for multidrug-resistant organism : efficacy and response prediction", J Infect, 81, pp.719~725 (2020)
- Lee JJ, "Alteration of gut microbiota in carbapenem-resistant Enterobacteriaceae carriers during fecal microbiota transplantation according to decolonization periods", Microorganisms, 9, pp.352~ (2021)